|Bid||0.19 x 0|
|Ask||0.20 x 0|
|Day's Range||0.1900 - 0.2000|
|52 Week Range||0.1300 - 0.3900|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.52|
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European partner. The preservative free therapeutic is a prescription product, currently approved in certain countries in Europe. Aequus has previously met with Health Canada to receive regulatory guidance regarding this therapeutic and expects to submit an application for regulatory approval in the second half of 2019 for this product, with minimal additional analytical data required to complete the data package.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three and nine months ended September 30, 2018 and associated Company developments. Year to date revenue for the nine months ended September 30, 2018 of $1,173,013, a 52% increase over the same period in 2017. Decrease in net losses of 31% over the same quarter last year, and an overall 34% decrease in losses for nine months ended September 30 when compared to the same time period in 2017.
Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc (CVE:AQS) since 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
A look at the shareholders of Aequus Pharmaceuticals Inc (CVE:AQS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...
Innovation in the pharmaceutical industry has come a long way in the last few decades, but with the ...